{"url_path":"/sec/imvt/8-k/2026-05-20/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1764013/0001764013-26-000062-index.html","accession_number":"0001764013-26-000062","cik":"0001764013","ticker":"IMVT","issuer_name":"Immunovant, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1764013/0001764013-26-000062-index.html","primary_entity_key":"0001764013","primary_entity_name":"Immunovant, Inc."},"word_count":155,"has_tables":true,"body_markdown":"Item 2.02. Results of Operations and Financial Condition.\n\nOn May 20, 2026, Immunovant, Inc. (“the Company”) issued a press release announcing its financial results for its fourth quarter and fiscal year ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nThe information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information in this Item 2.02 shall not be incorporated by reference in any filing with the U.S. Securities and Exchange Commission, or the SEC, made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing."}